282 related articles for article (PubMed ID: 30502020)
1. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
[TBL] [Abstract][Full Text] [Related]
2. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
3. O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes.
Hitri K; Kuttel MM; De Benedetto G; Lockyer K; Gao F; Hansal P; Rudd TR; Beamish E; Rijpkema S; Ravenscroft N; Bolgiano B
Vaccine; 2019 Jun; 37(29):3866-3875. PubMed ID: 31160100
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.
Rondini S; Micoli F; Lanzilao L; Hale C; Saul AJ; Martin LB
Clin Vaccine Immunol; 2011 Mar; 18(3):460-8. PubMed ID: 21248155
[TBL] [Abstract][Full Text] [Related]
5. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
Pulickal AS; Pollard AJ
Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
[No Abstract] [Full Text] [Related]
6. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
[TBL] [Abstract][Full Text] [Related]
7. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
Micoli F; Rondini S; Pisoni I; Proietti D; Berti F; Costantino P; Rappuoli R; Szu S; Saul A; Martin LB
Vaccine; 2011 Jan; 29(4):712-20. PubMed ID: 21115057
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi.
Rondini S; Micoli F; Lanzilao L; Pisoni I; Di Cioccio V; Saul AJ; Martin LB
J Infect Dev Ctries; 2012 Nov; 6(11):763-73. PubMed ID: 23277501
[TBL] [Abstract][Full Text] [Related]
9. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
11. A Salmonella typhi Vi conjugate vaccine.
Koul PA
N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
[No Abstract] [Full Text] [Related]
12. The need & the issues related to new-generation typhoid conjugate vaccines in India.
Vashishtha VM; Kalra A
Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
[TBL] [Abstract][Full Text] [Related]
13. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
Voysey M; Pollard AJ
Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
[TBL] [Abstract][Full Text] [Related]
14. Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever.
Giannelli C; Cappelletti E; Di Benedetto R; Pippi F; Arcuri M; Di Cioccio V; Martin LB; Saul A; Micoli F
J Pharm Biomed Anal; 2017 May; 139():143-147. PubMed ID: 28282600
[TBL] [Abstract][Full Text] [Related]
15. Detection of O-acetylated Vi polysaccharide of Salmonella enterica subspecies typhi by enzyme immunoassay.
Rijpkema S; Durrani Z; Lemercinier X; Jones C
Biologicals; 2004 Mar; 32(1):11-6. PubMed ID: 15026021
[TBL] [Abstract][Full Text] [Related]
16. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
18. Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay.
Ahmadi H; Tabaraie B; Maleknia S; Shapouri R; Nejati M; Pour Mirza Gholi F; Hedayati M; Sadati M; Zahednia S; Sharifat Salmani A
J Med Microbiol; 2013 Feb; 62(Pt 2):283-286. PubMed ID: 23105026
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
20. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
[No Abstract] [Full Text] [Related]
[Next] [New Search]
